Sudo Biosciences appoints new Chief Business Officer

Sudo Biosciences, a biopharmaceutical company that designs and develops a broad pipeline of TYK2 (tyrosine kinase 2) inhibitors, has announced the appointment of Imran Babar, Ph.D., as chief business officer.

Dr Babar has extensive experience in in healthcare strategy, life sciences finance, operations and business development.

Scott Byrd, CEO, Sudo Biosciences, said:

“Imran brings to Sudo extensive experience in corporate strategy and business development, as well as his track record of financing and building biotech companies. He is exactly the type of leader Sudo needs as we advance into our next phase of growth.

“Imran will be an invaluable asset to Sudo, and I look forward to working with him to advance the TYK2 pseudokinase programs in our pipeline, which are all uniquely positioned as potential best-in-class category leaders.”

Dr Babar was most recently co-founder of Arvada Therapeutics and the chief business officer of Cydan II –  an NEA and Pfizer Ventures-backed orphan drug accelerator.

Dr Babar was previous a vice president on the private equity team at OrbiMed Advisors, where he focused on evaluating investment opportunities, sourcing new deals and creating value for portfolio companies.

He is also co-founder and board member for Rare Genomics Institute –  a 501(c)3 non-profit dedicated to helping rare disease patients.

Dr Babar also worked as an associate at Cowen & Company on the biotechnology equity research team.

Imran Babar, Ph.D., chief business officer of Sudo Biosciences, said:

“I am excited to join Sudo Biosciences and apply my experience to help patients with auto-immune diseases.

“The team and investors are impressive, and I look forward to joining them to develop novel TYK2 precision therapeutics that will have a meaningful impact on patient lives.”